Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$7.97 – $17.52
9% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $293.51B | $301.98B | $305.07B | $363.78B | $410.50B | $461.51B | $508.64B | $503.15B |
| Cost of revenue | $131.90B | $142.17B | $150.77B | $173.19B | $194.42B | $219.01B | $236.66B | $245.86B |
| Gross profit | $161.61B | $159.81B | $154.30B | $190.59B | $216.08B | $242.50B | $271.98B | $257.29B |
| Gross margin | 55.1% | 52.9% | 50.6% | 52.4% | 52.6% | 52.5% | 53.5% | 51.1% |
| R&D | $19.58B | $21.76B | $22.52B | $26.78B | $31.06B | $31.40B | $31.45B | $29.35B |
| Operating income | $61.28B | $55.28B | $50.95B | $67.42B | $72.65B | $77.30B | $87.58B | $62.56B |
| EBITDA | $74.19B | $74.42B | $77.22B | $92.69B | $107.20B | $115.97B | $121.77B | $109.29B |
| Net income | $41.22B | $34.88B | $31.90B | $44.09B | $45.78B | $49.64B | $53.67B | $35.68B |
| Net margin | 14.0% | 11.6% | 10.5% | 12.1% | 11.2% | 10.8% | 10.6% | 7.1% |
| EPS (diluted) | 197.29 | 166.87 | 152.37 | 70.16 | 72.91 | 79.24 | 86.05 | 57.52 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2027 | $536.1B | $65.28 | $61.61–$68.89 | 1 |
| 2028 | $568.2B | $77.06 | $72.73–$81.32 | 1 |
| 2029 | $601.7B | $90.71 | $85.61–$95.72 | 1 |
| 2030 | $632.7B | $99.76 | $94.16–$105.28 | 1 |
Forward consensus · source: Financial Modeling Prep
SYSMEX CORP
No one on the platform currently holds SSMXF.
No tracked institution reports a position in SSMXF as of their last filing.
| Ex-date | Per share | Pay date |
|---|---|---|
| 2027-03-31 | $20.0000 | |
| 2026-09-30 | $20.0000 | |
| 2026-03-31 | $18.0000 | 2026-06-29 |
| 2026-03-31 | $1.0000 | 2026-06-29 |
| 2025-09-30 | $18.0000 | 2025-12-02 |
| 2025-09-30 | $1.0000 | 2025-12-02 |
| 2025-03-31 | $17.0000 | 2025-06-30 |
| 2024-09-30 | $15.0000 | 2024-12-03 |
| 2024-03-28 | $42.0000 | |
| 2023-09-29 | $42.0000 | 2023-12-04 |
No one on the platform has traded SSMXF yet.
| $7.1B |
| — |
| GIFOFGrifols, S.A. | $8.85 | +0.00% | $8.7B | — |
| SHPMFShanghai Pharmaceuticals Holding Co., Ltd | $1.46 | +0.00% | $8.5B | — |
Source: Financial Modeling Prep · peers by sector/industry
| Execution date | Ratio |
|---|---|
| 2024-03-28 | 3-for-1 |
| 2011-03-29 | 2-for-1 |
| 2005-09-27 | 2-for-1 |
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 0.1× earnings vs its 0.2× historical median P/E.
Fair value ≈ $19.37 · price $8.85 today
Fair-value line = the stock's median historical P/E × earnings. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.